piritrexim has been researched along with trimethoprim in 38 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (7.89) | 18.7374 |
| 1990's | 20 (52.63) | 18.2507 |
| 2000's | 9 (23.68) | 29.6817 |
| 2010's | 6 (15.79) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coats, EA; Genther, CS; Hansch, C; Selassie, CD; Strong, CD | 1 |
| Dias, CB; Hansch, C; Khwaja, TA; Pentecost, S; Selassie, CD | 1 |
| Queener, SF | 1 |
| Forsch, RA; Queener, SF; Rosowsky, A | 3 |
| Baccanari, DP; Boytos, CM; Chan, JH; Hong, JS; Joyner, SS; Kuyper, LF; Rudolph, SK; Tansik, RL | 1 |
| Gangjee, A; Kisliuk, RL; Queener, SF; Vasudevan, A | 1 |
| Gangjee, A; Mavandadi, F; McGuire, JJ; Queener, SF | 1 |
| Mota, CE; Queener, SF; Rosowsky, A; Wright, JE | 1 |
| Bertino, JR; Ercikan-Abali, E; Mota, CE; Queener, SF; Rosowsky, A; Waltham, M | 1 |
| Barrows, LR; Gangjee, A; Kisliuk, RL; Queener, SF; Shi, J | 1 |
| Broom, AD; Francom, P; Gangjee, A; Queener, SF; Zhu, Y | 1 |
| Baccanari, DP; Boytos, CM; Caddell, JM; Comley, JC; Friedman, HS; Hunter, RN; Jones, ML; Joyner, SS; Knick, V; Kuyper, LF; Rudolph, SK; Stables, JN; Tansik, RL; Wilson, HR | 1 |
| Borotz, SE; Carter, RL; Hosmer, CA; Johnson, CA; Krauth, CA; Pfefferkorn, ER; Piper, JR; Queener, SF | 1 |
| Devraj, R; Gangjee, A; Queener, SF | 1 |
| Gangjee, A; Queener, SF; Vasudevan, A | 1 |
| Gangjee, A; Mavandadi, F; Queener, SF | 1 |
| Papoulis, AT; Queener, SF; Rosowsky, A | 1 |
| Gangjee, A; Queener, SF; Zhu, Y | 1 |
| Forsch, RA; Papoulis, AT; Queener, SF; Rosowsky, A | 1 |
| Adair, O; Gangjee, A; Queener, SF | 1 |
| Aqvist, J; Graffner-Nordberg, M; Hallberg, A; Kolmodin, K; Queener, SF | 1 |
| Adair, OO; Gangjee, A; Queener, SF | 1 |
| Forsch, RA; Inderlied, CB; Queener, SF; Rosowsky, A; Sibley, CH | 1 |
| Chan, DC; Fu, H; Queener, SF; Rosowsky, A | 1 |
| Chan, DC; Forsch, RA; Fu, H; Queener, SF; Rosowsky, A | 1 |
| Adair, OO; Gangjee, A; Pagley, M; Queener, SF | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Cody, V; Gangjee, A; Kisliuk, RL; Namjoshi, OA; Queener, SF; Raghavan, S | 1 |
| Boesche, M; Crowther, GJ; Dasari, KS; Drewes, G; El Bakkouri, M; Fox, AM; Ghidelli-Disse, S; He, P; Hillesland, HK; Hui, R; Jones, JC; Keyloun, KR; Krahn, MM; Lafuente-Monasterio, MJ; Leonard, SE; Leroy, D; Maly, DJ; Mo, JS; Ojo, KK; Reid, MC; Rivas, KL; Van Voorhis, WC | 1 |
| Cody, V; Gangjee, A; Lin, X; Pace, J; Queener, SF; Shah, K | 1 |
| Cody, V; Gangjee, A; Pace, J; Queener, S; Shah, K | 1 |
| Feinberg, J; Sattler, FR | 1 |
| Chastang, C; Derouin, F | 1 |
| Bagnara, AS; Nott, SE | 1 |
1 review(s) available for piritrexim and trimethoprim
| Article | Year |
|---|---|
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.
Topics: Animals; Drug Design; Humans; Immunosuppression Therapy; Molecular Structure; Opportunistic Infections; Pneumonia, Pneumocystis; Structure-Activity Relationship | 1995 |
37 other study(ies) available for piritrexim and trimethoprim
| Article | Year |
|---|---|
Quantitative structure-activity relationship of antifolate inhibition of bacteria cell cultures resistant and sensitive to methotrexate.
Topics: Biological Transport, Active; Chemical Phenomena; Chemistry; Drug Resistance, Microbial; Escherichia coli; Folic Acid Antagonists; Lacticaseibacillus casei; Mathematics; Methotrexate; Pyrimethamine; Pyrimidines; Structure-Activity Relationship; Triazines | 1985 |
Comparative structure-activity relationships of antifolate triazines inhibiting murine tumor cells sensitive and resistant to methotrexate.
Topics: Animals; Chemical Phenomena; Chemistry, Physical; Chickens; Drug Resistance; Folic Acid Antagonists; Humans; Leukemia L5178; Leukemia, Experimental; Mathematics; Methotrexate; Mice; Structure-Activity Relationship; Triazines | 1984 |
2,4-Diaminopyrido[3,2-d]pyrimidine inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii.
Topics: Animals; Chromatography, Thin Layer; Folic Acid Antagonists; Liver; Magnetic Resonance Spectroscopy; Pneumocystis; Pyrimidines; Rats; Spectrophotometry, Infrared; Toxoplasma | 1995 |
Selective inhibitors of Candida albicans dihydrofolate reductase: activity and selectivity of 5-(arylthio)-2,4-diaminoquinazolines.
Topics: Animals; Antifungal Agents; Candida albicans; Drug Design; Folic Acid Antagonists; Humans; Mice; Pyrimethamine; Pyrimidines; Quinazolines; Recombinant Proteins; Structure-Activity Relationship; Trimethoprim; Trimetrexate | 1995 |
6-substituted 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
Topics: Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Folic Acid Antagonists; Pneumocystis; Pyrimidines; Rats; Toxoplasma | 1995 |
Novel 2,4-diamino-5-substituted-pyrrolo[2,3-d]pyrimidines as classical and nonclassical antifolate inhibitors of dihydrofolate reductases.
Topics: Folic Acid Antagonists; Humans; Peptide Synthases; Pyrimidines; Tumor Cells, Cultured | 1995 |
2,4-Diamino-5-chloroquinazoline analogues of trimetrexate and piritrexim: synthesis and antifolate activity.
Topics: Animals; Folic Acid Antagonists; Humans; Pyrimidines; Rats; Structure-Activity Relationship; Trimetrexate | 1994 |
2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
Topics: Animals; Folic Acid Antagonists; Humans; In Vitro Techniques; Liver; Mutagenesis, Site-Directed; Pneumocystis; Quinazolines; Rats; Structure-Activity Relationship; Toxoplasma | 1995 |
Synthesis of 5-methyl-5-deaza nonclassical antifolates as inhibitors of dihydrofolate reductases and as potential antipneumocystis, antitoxoplasma, and antitumor agents.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Folic Acid Antagonists; Fungal Proteins; Humans; Liver; Mice; Molecular Conformation; Neoplasms, Experimental; Oxidation-Reduction; Pneumocystis; Pneumocystis Infections; Protozoan Proteins; Pyrimidines; Rats; Structure-Activity Relationship; Toxoplasma | 1993 |
Nonclassical 2,4-diamino-8-deazafolate analogues as inhibitors of dihydrofolate reductases from rat liver, Pneumocystis carinii, and Toxoplasma gondii.
Topics: Animals; Folic Acid; Folic Acid Antagonists; Liver; Magnetic Resonance Spectroscopy; Methylation; Pneumocystis; Rats; Spectrometry, Mass, Fast Atom Bombardment; Spectrophotometry, Ultraviolet; Tetrahydrofolate Dehydrogenase; Toxoplasma | 1996 |
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
Topics: Animals; Anti-Infective Agents; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Candidiasis; Cell Division; Cell Line; Crystallography, X-Ray; Drug Design; Drug Resistance, Multiple; Enzyme Inhibitors; Folic Acid Antagonists; Humans; Lung Neoplasms; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Mice, Nude; Mice, SCID; Models, Molecular; Molecular Conformation; Molecular Structure; Molecular Weight; Pneumonia, Pneumocystis; Protein Structure, Secondary; Quinazolines; Structure-Activity Relationship; Toxoplasma; Tumor Cells, Cultured | 1996 |
Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
Topics: Animals; Anti-Infective Agents; Folic Acid Antagonists; Opportunistic Infections; Pneumocystis; Pneumonia, Pneumocystis; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma; Toxoplasmosis; Trimetrexate | 1996 |
Synthesis and dihydrofolate reductase inhibitory activities of 2,4-diamino-5-deaza and 2,4-diamino-5,10-dideaza lipophilic antifolates.
Topics: AIDS-Related Opportunistic Infections; Animals; Folic Acid Antagonists; Liver; Pyrimidines; Rats; Tetrahydrofolate Dehydrogenase; Trimetrexate | 1997 |
Synthesis and biological evaluation of nonclassical 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines with novel side chain substituents as potential inhibitors of dihydrofolate reductases.
Topics: AIDS-Related Opportunistic Infections; Animals; Folic Acid Antagonists; Humans; Liver; Mice; Pneumocystis; Pyrimidines; Rats; Tetrahydrofolate Dehydrogenase; Toxoplasma; Trimetrexate | 1997 |
Effect of N9-methylation and bridge atom variation on the activity of 5-substituted 2,4-diaminopyrrolo[2,3-d]pyrimidines against dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
Topics: Animals; Enzyme Inhibitors; Folic Acid Antagonists; Liver; Magnetic Resonance Spectroscopy; Methylation; Pneumocystis; Pyrimidines; Rats; Tetrahydrofolate Dehydrogenase; Toxoplasma | 1997 |
2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
Topics: Animals; Folic Acid Antagonists; Liver; Pneumocystis; Pyrimidines; Rats; Tetrahydrofolate Dehydrogenase; Toxoplasma; Trimethoprim | 1998 |
6-Substituted 2,4-diaminopyrido[3,2-d]pyrimidine analogues of piritrexim as inhibitors of dihydrofolate reductase from rat liver, Pneumocystis carinii, and Toxoplasma gondii and as antitumor agents.
Topics: Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Folic Acid Antagonists; Inhibitory Concentration 50; Liver; Pneumocystis; Pyrimidines; Rats; Structure-Activity Relationship; Toxoplasma; Tumor Cells, Cultured | 1998 |
Synthesis and antiparasitic and antitumor activity of 2, 4-diamino-6-(arylmethyl)-5,6,7,8-tetrahydroquinazoline analogues of piritrexim.
Topics: Animals; Antifungal Agents; Antineoplastic Agents; Antiprotozoal Agents; Cell Line; Drug Screening Assays, Antitumor; Folic Acid Antagonists; Humans; Liver; Lung; Mice; Pneumocystis; Pyrimidines; Quinazolines; Rats; Tetrahydrofolate Dehydrogenase; Toxoplasma; Toxoplasmosis, Animal; Tumor Cells, Cultured | 1999 |
Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)methyl] pyrido[2,3-d]pyrimidines.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Female; Folic Acid Antagonists; Humans; Mice; Mice, Inbred ICR; Pneumocystis; Pyrimidines; Rats; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma; Tumor Cells, Cultured | 1999 |
Design, synthesis, computational prediction, and biological evaluation of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii.
Topics: Animals; Esters; Folic Acid Antagonists; Humans; Ligands; Liver; Male; Models, Molecular; Pneumocystis; Pyrimidines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Trimetrexate | 2001 |
Inhibition of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductases by 2,4-diamino-5-[2-methoxy-5-(omega-carboxyalkyloxy)benzyl]pyrimidines: marked improvement in potency relative to trimethoprim and species selectivity
Topics: Animals; Folic Acid Antagonists; Liver; Mycobacterium avium; Pneumocystis; Pyrimidines; Rats; Species Specificity; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma; Trimethoprim | 2002 |
Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS.
Topics: AIDS-Related Opportunistic Infections; Animals; Benzyl Compounds; Folic Acid Antagonists; Liver; Magnetic Resonance Spectroscopy; Mycobacterium avium; Pneumocystis; Pyrimidines; Rats; Species Specificity; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma | 2003 |
Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
Topics: Animals; Anti-Infective Agents; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cricetinae; Drug Screening Assays, Antitumor; Female; Folic Acid Antagonists; Humans; Mice; Mice, Inbred BALB C; Opportunistic Infections; Pneumocystis carinii; Pyridines; Pyrimidines; Rats; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma; Toxoplasmosis | 2003 |
New 2,4-diamino-5-(2',5'-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity.
Topics: AIDS-Related Opportunistic Infections; Animals; Folic Acid Antagonists; Humans; Inhibitory Concentration 50; Liver; Microbial Sensitivity Tests; Mycobacterium avium; Opportunistic Infections; Pneumocystis carinii; Pyrimidines; Rats; Recombinant Proteins; Species Specificity; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma | 2004 |
Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridines as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase.
Topics: Animals; Azepines; Benzazepines; Folic Acid Antagonists; Models, Molecular; Mycobacterium avium; Pneumocystis carinii; Pteridines; Rats; Solubility; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma; Water | 2004 |
Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with omega-carboxyalkoxy or omega-carboxy-1-alkynyl substitution in the side chain.
Topics: Animals; Anti-Infective Agents; Drug Design; Folic Acid Antagonists; Models, Molecular; Molecular Structure; Mycobacterium avium; Pneumocystis carinii; Pyrimidines; Rats; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma | 2005 |
N9-substituted 2,4-diaminoquinazolines: synthesis and biological evaluation of lipophilic inhibitors of pneumocystis carinii and toxoplasma gondii dihydrofolate reductase.
Topics: Animals; Binding Sites; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Liver; Molecular Structure; Pneumocystis carinii; Quinazolines; Rats; Stereoisomerism; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.
Topics: Amination; Aniline Compounds; Crystallography, X-Ray; Drug Design; Folic Acid Antagonists; Humans; Models, Molecular; Mycobacterium avium; Pneumocystis carinii; Pyridines; Pyrimidines; Recombinant Proteins; Species Specificity; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase | 2013 |
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
Topics: Antimalarials; Calcium; Cell Line, Tumor; Hep G2 Cells; Humans; Malaria, Falciparum; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase Kinases; Plasmodium falciparum; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Protozoan Proteins | 2016 |
Targeting species specific amino acid residues: Design, synthesis and biological evaluation of 6-substituted pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors and potential anti-opportunistic infection agents.
Topics: Amino Acids; Anti-Bacterial Agents; Catalytic Domain; Crystallography, X-Ray; Drug Design; Enzyme Assays; Folic Acid Antagonists; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Molecular Docking Simulation; Molecular Structure; Pneumocystis carinii; Protein Binding; Pyrimidines; Pyrroles; Sequence Homology, Amino Acid; Species Specificity; Tetrahydrofolate Dehydrogenase | 2018 |
Development of substituted pyrido[3,2-d]pyrimidines as potent and selective dihydrofolate reductase inhibitors for pneumocystis pneumonia infection.
Topics: Folic Acid Antagonists; Humans; Models, Molecular; Pneumocystis; Pneumocystis carinii; Pyrimidines; Structure-Activity Relationship; Trimethoprim | 2019 |
New developments in the treatment of Pneumocystis carinii pneumonia.
Topics: Adrenal Cortex Hormones; Aerosols; Dapsone; Drug Therapy, Combination; Eflornithine; Folic Acid Antagonists; Humans; Pentamidine; Pneumonia, Pneumocystis; Pyrimidines; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination; Trimetrexate | 1992 |
In vitro effects of folate inhibitors on Toxoplasma gondii.
Topics: Animals; Enzyme-Linked Immunosorbent Assay; Folic Acid Antagonists; Microbial Sensitivity Tests; Pyrimethamine; Pyrimidines; Quinazolines; Sulfamethoxazole; Sulfisoxazole; Toxoplasma; Trimethoprim; Trimetrexate | 1989 |
The toxicity of antifolates in Babesia bovis.
Topics: Animals; Babesia bovis; Folic Acid; Folic Acid Antagonists; Pyrimethamine; Pyrimidines; Quinazolines; Trimethoprim; Trimetrexate | 1993 |